Clinical and molecular characteristics of CA-AML patients
| Characteristic . | miRNA array sets (n = 86) . | mRNA array sets (n = 454) . | ||||
|---|---|---|---|---|---|---|
| Training set (n = 183) . | Validation set (n = 271) . | |||||
| USA-set-I (n = 33)33 . | USA-set-II (n = 53) . | USA-set-II-35S (n = 35)* . | USA-set-III (n = 87) . | Germany-set-I20 (n = 61) . | Netherlands-set-I32 (n = 271) . | |
| Sex, no. (%) | ||||||
| Male | 11 (33) | 27 (51) | 20 (57) | 46 (53) | 35 (57) | 138 (51) |
| Female | 22 (67) | 26 (49) | 15 (43) | 41 (47) | 26 (43) | 133 (49) |
| Age, y | ||||||
| Median | 41 | 56 | 44 | 41 | 48 | 43 |
| Range | 5-87 | 0-84 | 0-84 | 0-74 | 19-74 | 15-74 |
| OS, y | ||||||
| Median | 3 | 2 | 2 | 6 | 1 | 2 |
| Range | 0-25 | 0-16 | 0-16 | 0-13 | 0-4 | 0-19 |
| White cell count, 1 × 10−3/mm3 | ||||||
| Median | NA | 30 | 24 | 20 | 29 | 21 |
| Range | NA | 0.5-182 | 0.8-182 | 0.3-206 | 1-189 | 1.3-510 |
| Blast cell count, % | ||||||
| Median | 95 | 44 | 35 | 65 | NA | 62 |
| Range | 10-100 | 0-94 | 0-88 | 3-95 | NA | 0-98 |
| Platelet count, 1 × 10−3/mm3 | ||||||
| Median | NA | 48 | 47 | 30 | NA | 50 |
| Range | NA | 13-263 | 16-164 | 6-138 | NA | 3-998 |
| FAB type, no. (%) | ||||||
| M0 | 0 | 1 (2) | 1 (3) | 0 | 2 (3) | 13 (5) |
| M1 | 2 (6) | 4 (8) | 2 (6) | 0 | 6 (10) | 39 (14) |
| M2 | 5 (15) | 8 (15) | 6 (17) | 29 (33) | 14 (23) | 71 (26) |
| M3 | 8 (24) | 9 (17) | 8 (23) | 31 (36) | 9 (15) | 18 (7) |
| M4 | 8 (24) | 11 (21) | 8 (23) | 23 (26) | 18 (30) | 58 (21) |
| M5 | 8 (24) | 7 (13) | 5 (14) | 4 (5) | 8 (13) | 49 (18) |
| M6 | 0 | 0 | 0 | 0 | 0 | 4 (1) |
| Not determined | 2 (6) | 13 (24) | 5 (14) | 0 | 4 (7) | 19 (7) |
| Cytogenetic abnormalities, no. (%) | ||||||
| t(15;17) | 7 (21) | 9 (17) | 8 (23) | 31 (36) | 9 (15) | 19 (7) |
| t(8;21) | 7 (21) | 9 (17) | 5 (14) | 29 (33) | 9 (15) | 37 (14) |
| inv(16)/t(16;16) | 4 (12) | 9 (17) | 7 (20) | 22 (25) | 15 (25) | 38 (14) |
| t(11q23) | 15 (45) | 10 (19) | 7 (20) | 5 (6) | 7 (11) | 16 (6) |
| +8 | 0 | 10 (19) | 5 (14) | 0 | 2 (3) | 37 (14) |
| −7/del(7q) | 0 | 2 (4) | 1 (3) | 0 | 10 (16) | 35 (13) |
| −3/inv(3)/t(3;3) | 0 | 0 | 0 | 0 | 0 | 20 (7) |
| t(6;9) | 0 | 0 | 0 | 0 | 0 | 5 (2) |
| t(9;22) | 0 | 0 | 0 | 0 | 0 | 5 (2) |
| Complex karyotype | 0 | 0 | 0 | 0 | 4 (7) | 31 (11) |
| Other abnormal karyotype | 0 | 4 (8) | 2 (6) | 0 | 5 (8) | 80 (30) |
| Not determined | 0 | 0 | 0 | 0 | 0 | 0 |
| Molecular abnormalities, no. (%) | ||||||
| FLT3-ITD or -TKD | NA | NA | NA | NA | 12 (20) | 63 (23) |
| N- or K-RAS | NA | NA | NA | NA | NA | 31 (11) |
| NPM1 | NA | NA | NA | NA | NA | 24 (9) |
| CEBPA | NA | NA | NA | NA | NA | 11 (4) |
| MLL-PTD | NA | NA | NA | NA | 2 (3) | NA |
| Characteristic . | miRNA array sets (n = 86) . | mRNA array sets (n = 454) . | ||||
|---|---|---|---|---|---|---|
| Training set (n = 183) . | Validation set (n = 271) . | |||||
| USA-set-I (n = 33)33 . | USA-set-II (n = 53) . | USA-set-II-35S (n = 35)* . | USA-set-III (n = 87) . | Germany-set-I20 (n = 61) . | Netherlands-set-I32 (n = 271) . | |
| Sex, no. (%) | ||||||
| Male | 11 (33) | 27 (51) | 20 (57) | 46 (53) | 35 (57) | 138 (51) |
| Female | 22 (67) | 26 (49) | 15 (43) | 41 (47) | 26 (43) | 133 (49) |
| Age, y | ||||||
| Median | 41 | 56 | 44 | 41 | 48 | 43 |
| Range | 5-87 | 0-84 | 0-84 | 0-74 | 19-74 | 15-74 |
| OS, y | ||||||
| Median | 3 | 2 | 2 | 6 | 1 | 2 |
| Range | 0-25 | 0-16 | 0-16 | 0-13 | 0-4 | 0-19 |
| White cell count, 1 × 10−3/mm3 | ||||||
| Median | NA | 30 | 24 | 20 | 29 | 21 |
| Range | NA | 0.5-182 | 0.8-182 | 0.3-206 | 1-189 | 1.3-510 |
| Blast cell count, % | ||||||
| Median | 95 | 44 | 35 | 65 | NA | 62 |
| Range | 10-100 | 0-94 | 0-88 | 3-95 | NA | 0-98 |
| Platelet count, 1 × 10−3/mm3 | ||||||
| Median | NA | 48 | 47 | 30 | NA | 50 |
| Range | NA | 13-263 | 16-164 | 6-138 | NA | 3-998 |
| FAB type, no. (%) | ||||||
| M0 | 0 | 1 (2) | 1 (3) | 0 | 2 (3) | 13 (5) |
| M1 | 2 (6) | 4 (8) | 2 (6) | 0 | 6 (10) | 39 (14) |
| M2 | 5 (15) | 8 (15) | 6 (17) | 29 (33) | 14 (23) | 71 (26) |
| M3 | 8 (24) | 9 (17) | 8 (23) | 31 (36) | 9 (15) | 18 (7) |
| M4 | 8 (24) | 11 (21) | 8 (23) | 23 (26) | 18 (30) | 58 (21) |
| M5 | 8 (24) | 7 (13) | 5 (14) | 4 (5) | 8 (13) | 49 (18) |
| M6 | 0 | 0 | 0 | 0 | 0 | 4 (1) |
| Not determined | 2 (6) | 13 (24) | 5 (14) | 0 | 4 (7) | 19 (7) |
| Cytogenetic abnormalities, no. (%) | ||||||
| t(15;17) | 7 (21) | 9 (17) | 8 (23) | 31 (36) | 9 (15) | 19 (7) |
| t(8;21) | 7 (21) | 9 (17) | 5 (14) | 29 (33) | 9 (15) | 37 (14) |
| inv(16)/t(16;16) | 4 (12) | 9 (17) | 7 (20) | 22 (25) | 15 (25) | 38 (14) |
| t(11q23) | 15 (45) | 10 (19) | 7 (20) | 5 (6) | 7 (11) | 16 (6) |
| +8 | 0 | 10 (19) | 5 (14) | 0 | 2 (3) | 37 (14) |
| −7/del(7q) | 0 | 2 (4) | 1 (3) | 0 | 10 (16) | 35 (13) |
| −3/inv(3)/t(3;3) | 0 | 0 | 0 | 0 | 0 | 20 (7) |
| t(6;9) | 0 | 0 | 0 | 0 | 0 | 5 (2) |
| t(9;22) | 0 | 0 | 0 | 0 | 0 | 5 (2) |
| Complex karyotype | 0 | 0 | 0 | 0 | 4 (7) | 31 (11) |
| Other abnormal karyotype | 0 | 4 (8) | 2 (6) | 0 | 5 (8) | 80 (30) |
| Not determined | 0 | 0 | 0 | 0 | 0 | 0 |
| Molecular abnormalities, no. (%) | ||||||
| FLT3-ITD or -TKD | NA | NA | NA | NA | 12 (20) | 63 (23) |
| N- or K-RAS | NA | NA | NA | NA | NA | 31 (11) |
| NPM1 | NA | NA | NA | NA | NA | 24 (9) |
| CEBPA | NA | NA | NA | NA | NA | 11 (4) |
| MLL-PTD | NA | NA | NA | NA | 2 (3) | NA |
NA indicates information not available; and FAB, French-American-British.
USA-set-II-35S patients were included in both miRNA and mRNA microarrays, and this set is a part of the USA-set-II.